Activating mutations and gene fusions involving FGFR2 were mutually exclusive with these and identified in 4% [10] and 10–15% [11, 12] of intrahepatic bile duct carcinomas, respectively. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.